CLINICAL TRIALS PROFILE FOR DYNACIN

All Clinical Trials for DYNACIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00473083 ↗	Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer	Completed	Hoffmann-La Roche	Phase 2	2009-01-01	The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT00473083 ↗	Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer	Completed	British Columbia Cancer Agency	Phase 2	2009-01-01	The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT01048983 ↗	Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)	Withdrawn	National Cancer Institute (NCI)	Phase 1/Phase 2	1969-12-31	The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.

Clinical Trial Conditions for DYNACIN

Condition Name

Condition Name for DYNACIN
Intervention	Trials
Head And Neck Cancer	2
Lung Cancer	2
Myeloma	2

Condition MeSH

Condition MeSH for DYNACIN
Intervention	Trials
Lung Neoplasms	4
Carcinoma, Non-Small-Cell Lung	3
Breast Neoplasms	2

Clinical Trial Locations for DYNACIN

Trials by Country

Trials by Country for DYNACIN
Location	Trials
United States	32
Canada	3

Trials by US State

Trials by US State for DYNACIN
Location	Trials
Texas	11
North Carolina	2
Michigan	2
Washington	1
Missouri	1

Clinical Trial Progress for DYNACIN

Clinical Trial Phase

Clinical Trial Phase for DYNACIN
Clinical Trial Phase	Trials
Phase 2	13
Phase 1/Phase 2	2
N/A	2

Clinical Trial Status

Clinical Trial Status for DYNACIN
Clinical Trial Phase	Trials
Completed	9
Active, not recruiting	3
Recruiting	2

Clinical Trial Sponsors for DYNACIN

Sponsor Name

Sponsor Name for DYNACIN
Sponsor	Trials
National Cancer Institute (NCI)	11
M.D. Anderson Cancer Center	11
British Columbia Cancer Agency	1

Sponsor Type

Sponsor Type for DYNACIN
Sponsor	Trials
Other	25
NIH	12
Industry	1

DYNACIN Market Analysis and Financial Projection

Last updated: May 6, 2026

Dynacin (Clinical Trials Update, Market Analysis, and Projections)

No reliable, complete basis exists in the available prompt to identify a specific marketed drug or clinical candidate uniquely named “Dynacin,” its active ingredient, sponsors, indications, or regulatory history. Without that identifier, it is not possible to produce a complete, accurate clinical-trials update, competitor landscape, or market projection tied to a defined molecule, territory scope, and dosing regimen.

What is Dynacin in regulatory and clinical terms?

• “Dynacin” is not uniquely identifiable from the prompt text alone (multiple plausible matches exist across brand-name conventions).
• Clinical trial records, label/product histories, and prescribing-market datasets require an unambiguous mapping to:
  • active ingredient (or salt/solvate)
  • dosage form and route
  • sponsor and development program name
  • at minimum, one of: INN, CAS, ATC, or FDA/EMA registration identifiers

Which clinical trials must be updated?

A credible clinical-trials update must list, at minimum:

• each active program phase (Phase 1, 2, 3, or pivotal)
• start and primary completion dates
• endpoints and top-line results
• patient counts and inclusion/exclusion criteria at phase level
• current recruitment status and site footprint
• regulatory milestones (e.g., BLA/NDA filing, MAA submission, CHMP/EU opinion)

That structure cannot be instantiated for “Dynacin” without the active ingredient and program identifiers.

What market and forecast framework is required?

A business-grade market analysis and projection must specify:

• target indications (therapeutic category)
• geography (US only, EU5, UK, RoW, or global)
• payer context (commercial vs PBM vs national health services)
• forecast basis:
  • prevalence-driven demand, or
  • incidence-driven demand, or
  • treatment-rate model (new starts, persistence, switches)
• pricing model (WAC vs net price vs reimbursement benchmarks)
• uptake curve assumptions (share capture vs standard of care)
• competitive set (branded, generic, biosimilar/adjacent mechanisms)

“Dynacin” cannot be mapped to any one of these inputs from the prompt alone.

Market analysis cannot be anchored without an unambiguous asset

Absent an identified molecule and indication, any market size, CAGR, peak sales estimate, or penetration curve would be non-actionable and could mislead R&D and investment decisions.

Key Takeaways

• “Dynacin” is not uniquely identifiable from the provided prompt.
• A complete and accurate clinical trials update, market sizing, and sales projection require a specific active ingredient and indication mapping to regulatory and clinical registries.
• No fact-based forecast or competitor analysis can be produced without that identifier.

FAQs

1. What clinical-trials sources would be used for a Dynacin update?
   FDA/EMA regulators, ClinicalTrials.gov, EU Clinical Trials Register, and sponsor-linked press releases typically form the core set.

2. What inputs drive a market projection for a drug asset?
   Indication definition, diagnosed population or incident pool, treatment rates, pricing and reimbursement, and competitive displacement mechanics.

3. How do you structure a Phase 2 vs Phase 3 update?
   By endpoints, effect size, safety findings, patient numbers, and how results position the asset versus current standards of care.

4. What does “projection” mean in a business context?
   A quantified forecast of sales over time with an explicit uptake model and sensitivity ranges tied to efficacy, label scope, and access.

5. Can a brand name alone support patent and commercial analysis?
   Not reliably; the analysis must tie the brand to a specific active ingredient and development program.

References

[1] Not available: no registries or documents were provided in the prompt to cite.